SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549
                                    Form 10-Q

(Mark One)

( X )    QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
         ACT OF 1934

For the quarterly period ended:                      December 31, 2002
                                    ------------------------------------------

(  )     TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE EXCHANGE ACT

For the transition period from:                                to
                                    --------------------------    ------------

Commission file number:                                       0-13265
                                    ------------------------------------------

                              UCI MEDICAL AFFILIATES, INC.
----------------------------------------------------------------
    (Exact name of small business issuer as specified in its charter)

Delaware                                            59-2225346
(State or other jurisdiction of incorporation (IRS Employer Identification No.)
  or organization)

                    4416 Forest Drive, Columbia, SC 29206
                    (Address of principal executive offices)

                               (803) 782-4278
                           (Issuer's telephone number)


       (Former name, address or fiscal year, if changed since last report)

Indicate by checkmark whether the issuer (1) has filed all reports required to
be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12
months (or for such shorter period that the registrant was required to file such
reports), and (2) has been subject to such filing requirements for the past 90
days. ( X )Yes ( ) No

     Indicate by checkmark  whether the registrant is an  accelerated  filer (as
defined in Rule 12b-2 of the Exchange Act). ( ) Yes ( X ) No

                APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
                   PROCEEDINGS DURING THE PRECEDING FIVE YEARS

     Indicate  by  checkmark  whether the  registrant  filed all  documents  and
reports  required  to be filed by Section 12, 13, or 15(d) of the  Exchange  Act
after the distribution of securities under a plan confirmed by a court. ( X )Yes
( ) No


                      APPLICABLE ONLY TO CORPORATE ISSUERS

Indicate the number of shares outstanding of each of the issuer's classes of
common equity, as of the latest practicable date:

    9,650,515 shares of $.05 common stock outstanding at December 31, 2002
-------------------------------------------------------------------------------



<PAGE>


                          UCI MEDICAL AFFILIATES, INC.

                                      INDEX

<TABLE>
<S>                                                                                             <C>
                                                                                                   Page
                                                                                                 Number

PART I            FINANCIAL INFORMATION

                  Item 1   Financial Statements

                           Condensed Consolidated Balance Sheets - December 31, 2002
                           and September 30, 2002                                                     3

                           Condensed Consolidated Statements of Operations for the quarters
                           ended December 31, 2002 and December 31, 2001                              4

                           Condensed Consolidated Statements of Cash Flows for the quarters
                           ended December 31, 2002 and December 31, 2001                              5

                           Notes to Condensed Consolidated Financial Statements                 6  -  8

                  Item 2   Management's Discussion and Analysis of Financial
                           Condition and Results of Operations                                  9 -  13

                  Item 3   Quantitative and Qualitative Disclosures About Market Risk                14

                  Item 4   Controls and Procedures                                              15 - 16

PART II           OTHER INFORMATION

                  Items 1-6                                                                     17 - 18


SIGNATURES                                                                                           19

</TABLE>





<PAGE>


                          UCI Medical Affiliates, Inc.
                      Condensed Consolidated Balance Sheets
<TABLE>
<S>                                                                    <C>                   <C>
                                                                       December 31, 2002       September 30,
                                                                                                    2002
                                                                       -------------------    -----------------

(unaudited) (audited)
Assets
Current assets
   Cash and cash equivalents                                                   $   57,487     $       269,298
   Accounts receivable, less allowance for doubtful accounts
       of $1,703,269 and $1,661,047                                             6,691,072           6,349,629
   Inventory                                                                      393,795             393,795
   Prepaid expenses and other current assets                                      514,777             297,178
                                                                       -------------------    -----------------
Total current assets                                                            7,657,131           7,309,900

Property and equipment less accumulated depreciation of
   $8,384,583 and $8,149,811                                                    3,747,169           3,764,545
Excess of cost over fair value of assets acquired, less
   accumulated amortization of $2,451,814 and $2,451,814                        3,391,942           3,391,942
Other assets                                                                       50,483              50,483
                                                                       -------------------    -----------------
Total Assets                                                                $  14,846,725     $    14,516,870
                                                                       ===================    =================

Liabilities and Stockholders' Equity
Current liabilities
   Current portion of long-term debt                                      $       998,397     $
                                                                                                    1,014,829
   Accounts payable                                                               707,281             762,646
   Accrued salaries and payroll taxes                                           1,425,357           1,514,745
   Current portion of pre-petition payroll taxes                                  456,139             475,079
   Other accrued liabilities                                                    1,014,514           1,027,299
                                                                       -------------------    -----------------
Total current liabilities                                                       4,601,688           4,794,598

Long-term liabilities
   Accounts payable                                                             2,652,797           2,083,167
   Long-term portion of pre-petition payroll taxes                              4,252,263           4,385,060
   Long-term debt, net of current portion                                       2,777,277           3,063,649
                                                                       -------------------    -----------------
                                                                       -------------------    -----------------
Total long-term liabilities                                                     9,682,337           9,531,876
                                                                       -------------------    -----------------
Total Liabilities                                                              14,284,025          14,326,474
                                                                       -------------------    -----------------

Commitments and contingencies

Stockholders' Equity
   Preferred stock, par value $.01 per share:
      Authorized shares - none issued; 10,000,000                                   --                     --
   Common stock, par value $.05 per share:
      Authorized shares - 50,000,000
      Issued and outstanding- 9,650,515 and 9,650,515 shares                      482,526             482,526
   Paid-in capital                                                             21,723,628          21,723,628
   Accumulated deficit                                                       (21,643,454)         (22,015,758)
                                                                       -------------------    -----------------
Total Stockholders' Equity                                                        562,700             190,396
                                                                       -------------------    -----------------

Total Liabilities and Stockholders' Equity                                  $  14,846,725     $    14,516,870
                                                                       ===================    =================
</TABLE>

                   The accompanying notes are an integral part of these
condensed consolidated financial statements.

<PAGE>


                          UCI Medical Affiliates, Inc.
                 Condensed Consolidated Statements of Operations
                                   (unaudited)
<TABLE>
<S>                                                           <C>                      <C>

                                                                            Three Months Ended December 31,
                                                                     2002                    2001
                                                              --------------------     ------------------

Revenues                                                              $10,296,744             $9,230,506
Operating costs                                                         9,472,378              8,550,911
                                                              --------------------     ------------------
Operating margin                                                          824,366                679,595

General and administrative expenses                                        22,010                 17,000
Depreciation and amortization                                             234,772                262,919
                                                              --------------------     ------------------
Income (loss) from operations                                             567,584                399,676

Other income (expense)
   Interest expense, net of interest income                             (195,280)              (201,644)
                                                              --------------------     ------------------
                                                              --------------------     ------------------

Income before benefit (provision) for income taxes                        372,304                198,032
Benefit (provision) for income taxes                                       --                       --
                                                              --------------------     ------------------

Net income                                                              $ 372,304              $ 198,032
                                                                                       ==================
                                                              ====================

Basic earnings per share                                                 $    .04               $    .02
                                                              ====================     ==================

Basic weighted average common shares outstanding                        9,650,515              9,650,515
                                                              ====================     ==================

Diluted earnings per share                                               $    .04               $    .02
                                                              ====================     ==================

Diluted weighted average common shares outstanding                      9,650,515              9,652,811
                                                              ====================     ==================
</TABLE>

                   The accompanying notes are an integral part of these
condensed consolidated financial statements.



<PAGE>


                          UCI Medical Affiliates, Inc.
                 Condensed Consolidated Statements of Cash Flows
                                   (unaudited)


<TABLE>
<S>                                                              <C>                  <C>
                                                                             Three Months Ended December 31,
                                                                       2002                  2001
                                                                 ------------------    -----------------
Operating activities:
Net income                                                               $ 372,304            $ 198,032
Adjustments to reconcile net income (loss) to net
   cash provided by operating activities:
      Provision for losses on accounts receivable                          410,463              463,107
      Depreciation and amortization                                        234,772              262,919
Changes in operating assets and liabilities:
   (Increase) decrease in accounts receivable                            (751,906)            (554,355)
   (Increase) decrease in prepaid expenses and other
      current assets                                                     (217,599)              361,863
   Increase (decrease) in accounts payable and accrued
      expenses                                                             260,355              264,288
                                                                                       -----------------
                                                                 ------------------

Cash provided by operating activities                                      308,389              995,854
                                                                 ------------------    -----------------

Investing activities:
Purchases of property and equipment                                      (217,396)             (46,133)
(Increase) decrease in other assets                                           --               (10,625)
                                                                                       -----------------
                                                                 ------------------

Cash used in investing activities                                        (217,396)             (56,758)
                                                                 ------------------    -----------------

Financing activities:
Payments on long-term debt                                               (302,804)            (669,667)
                                                                 ------------------    -----------------

Cash used in financing activities                                        (302,804)            (669,667)
                                                                 ------------------    -----------------

(Decrease) increase in cash and cash equivalents                         (211,811)              269,429
Cash and cash equivalents at beginning of period                           269,298               99,429
                                                                 ------------------    -----------------
                                                                 ------------------

Cash and cash equivalents at end of period                                $ 57,487            $ 368,858
                                                                 ==================    =================
</TABLE>

                   The accompanying notes are an integral part of these
condensed consolidated financial statements.


<PAGE>


                          UCI MEDICAL AFFILIATES, INC.

              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                                   (unaudited)


NOTE 1.  BUSINESS AND BASIS OF PRESENTATION:

The accompanying unaudited condensed consolidated financial statements have been
prepared in accordance with generally accepted accounting principles for interim
financial information and with the instructions to Form 10-Q and Article 10 of
Regulation S-X of the Securities and Exchange Commission. Accordingly, they do
not include all of the information and footnotes required by generally accepted
accounting principles for complete financial statements. In the opinion of
management, all adjustments (consisting only of those of a normal recurring
nature) considered necessary for a fair presentation have been included.
Operating results for the three-month period ended December 31, 2002 are not
necessarily indicative of the results that may be expected for the fiscal year
ending September 30, 2003. For further information, refer to the audited
consolidated financial statements and footnotes thereto included in our annual
report on Form 10-K for the year ended September 30, 2002.

The consolidated financial statements include the accounts of UCI Medical
Affiliates, Inc. ("UCI"), UCI Medical Affiliates of South Carolina, Inc.
("UCI-SC"), UCI Medical Affiliates of Georgia, Inc. ("UCI-GA"), Doctor's Care,
P.A., Doctor's Care of Georgia, P.C., and Doctor's Care of Tennessee, P.C. (the
three together as the "P.A." and together with UCI, UCI-SC and UCI-GA, the
"Company"). Because of the corporate practice of medicine laws in the states in
which the Company operates, the Company does not own medical practices but
instead enters into exclusive long-term management services agreements with the
P.A. which operate the medical practices. Consolidation of the financial
statements is required under Emerging Issues Task Force (EITF) 97-2 as a
consequence of the nominee shareholder arrangement that exists with respect to
each of the P.A.'s. In each case, the nominee (and sole) shareholder of the P.A.
has entered into an agreement with UCI-SC or UCI-GA, as applicable, which
satisfies the requirements set forth in footnote 1 of EITF 97-2. Under the
agreement, UCI-SC or UCI-GA, as applicable, in its sole discretion, can effect a
change in the nominee shareholder at any time for a payment of $100 from the new
nominee shareholder to the old nominee shareholder, with no limits placed on the
identity of any new nominee shareholder and no adverse impact resulting to any
of UCI-SC, UCI-GA or the P.A. resulting from such change.

In addition to the nominee shareholder arrangements described above, each of
UCI-SC and UCI-GA have entered into Administrative Service Agreements with the
P.A.'s. As a consequence of the nominee shareholder arrangements and the
Administrative Service Agreements, the Company has a long-term financial
interest in the affiliated practices of the P.A.'s through the Administrative
Services Agreement, and the Company has exclusive authority over decision making
relating to all major on-going operations. The Company establishes annual
operating and capital budgets for the P.A. and compensation guidelines for the
licensed medical professionals. The Administrative Services Agreements have an
initial term of forty years. According to EITF 97-2, the application of
Financial Accounting Standards Board ("FASB") Statement No. 94 (Consolidation of
All Majority-Owned Subsidiaries), and FASB 141 (Business Combinations), the
Company must consolidate the results of the affiliated practices with those of
the Company. All significant intercompany accounts and transactions are
eliminated in consolidation, including management fees.

The method of computing the management fees is based on billings of the
affiliated practices less the amounts necessary to pay professional compensation
and other professional expenses. In all cases, these fees are meant to
compensate the Company for expenses incurred in providing covered services plus
a profit. These interests are unilaterally salable and transferable by the
Company and fluctuate based upon the actual performance of the operations of the
professional corporation.

The P.A. enters into employment agreements with physicians for terms ranging
from one to three years. All employment agreements have clauses that allow for
early termination of the agreement if certain events occur such as the loss of a
medical license.

The preparation of financial statements in conformity with generally accepted
accounting principles requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and revenues and expenses
and the disclosure of contingent assets and liabilities. Actual results could
differ from those estimates and assumptions. Significant estimates are discussed
in these footnotes, as applicable.

The inventory of medical supplies and drugs is carried at the lower of average
cost (first in, first out) or market. The volume of supplies carried at a center
varies very little from month to month and management, therefore, does only an
annual physical inventory count and does not maintain a perpetual inventory
system.

The Company operates as one segment.


NOTE 2.  BUSINESS COMBINATIONS AND INTANGIBLES

     In June 2001, the Financial Accounting Standards Board issued SFAS No. 141,
"Business  Combinations"  and SFAS  No.  142,  "Goodwill  and  Other  Intangible
Assets". SFAS No. 141 requires that all business combinations  consummated after
June 30, 2001 be accounted for under the purchase method of accounting. SFAS No.
142 requires that goodwill and intangible  assets with indefinite  lives will no
longer be  amortized,  but are reviewed at least  annually for  impairment.  The
amortization  provisions  of SFAS No.  142 apply to  goodwill  and  intangibles.
Pursuant  to SFAS No.  142,  we tested  goodwill  for  impairment  in the fourth
quarter of 2002, and we determined there had not been any impairment.


NOTE 3.  EARNINGS PER SHARE

The computation of basic earnings (loss) per share and diluted earnings (loss)
per share is in conformity with the provisions of Statement of Financial
Accounting Standards No. 128.


NOTE 4.  NEW ACCOUNTING PRONOUNCEMENTS

In June 2002, the Financial Accounting Standards Board issued SFAS No. 146,
"Accounting for Exit or Disposal Activities". SFAS No. 146 addresses the
recognition, measurement and reporting of costs associated with exit and
disposal activities, including restructuring activities. SFAS No. 146 also
addresses recognition of certain costs related to terminating a contract that is
not a capital lease, costs to consolidate facilities or relocate employees and
termination of benefits provided to employees that are involuntarily terminated
under the terms of a one-time benefit arrangement that is not an ongoing benefit
arrangement or an individual deferred compensation contract. SFAS No. 146 is
effective for exit or disposal activities that are initiated after December 31,
2002. Adoption of SFAS No. 146 is not expected to have an impact on the
financial position or results of operations of the Company.


NOTE 5.  CHAPTER 11 BANKRUPTCY FILING

On November 2, 2001, the Company filed a voluntary petition for reorganization
under Chapter 11 of the United States Bankruptcy Code (the "Bankruptcy Code") in
the United States Bankruptcy Court for the District of South Carolina (the
"Bankruptcy Court"). As debtors-in-possession, the Company remained in
possession of its properties and assets, and its management continued to operate
its business. As debtors-in-possession, the Company was authorized to continue
to operate its businesses, but it was not allowed to engage in transactions
outside the ordinary course of business without the approval, after notice and
an opportunity for a hearing, of the Bankruptcy Court. Pursuant to the automatic
stay provisions of the Bankruptcy Code, all actions to collect pre-petition
indebtedness from the Company, as well as most other pending litigation against
the Company, were stayed. In addition, as debtors-in-possession, the Company had
the right, subject to the approval of the Bankruptcy Court and certain other
conditions, to assume or reject any pre-petition executory contracts or
unexpired leases.

The Bankruptcy Court approved payment of certain pre-petition liabilities, such
as employee wages and benefits and settlement of certain trade payable claims.
In addition, the Bankruptcy Court allowed for the retention of legal and
financial professionals to advise in the bankruptcy proceedings.

The Bankruptcy Court confirmed each of the Company's Plans of Reorganization, as
amended, by August 8, 2002, and the Company has, therefore, emerged from the
Chapter 11 protection of the Court.






<PAGE>


               Advisory Note Regarding Forward-Looking Statements

Certain of the statements contained in this Report on Form 10-Q that are not
historical facts are forward-looking statements subject to the safe harbor
created by the Private Securities Litigation Reform Act of 1995. We caution
readers of this Form 10-Q that such forward-looking statements involve known and
unknown risks, uncertainties and other factors that may cause our actual
results, performance or achievements to be materially different from those
expressed or implied by such forward-looking statements. Although our management
believes that their expectations of future performance are based on reasonable
assumptions within the bounds of their knowledge of their business and
operations, we have no assurance that actual results will not differ materially
from their expectations. Factors that could cause actual results to differ from
expectations include, among other things, (1) the difficulty in controlling our
costs of providing healthcare and administering our network of centers; (2) the
possible negative effects from changes in reimbursement and capitation payment
levels and payment practices by insurance companies, healthcare plans,
government payors and other payment sources; (3) the difficulty of attracting
primary care physicians; (4) the increasing competition for patients among
healthcare providers; (5) possible government regulations negatively impacting
our existing organizational structure; (6) the possible negative effects of
prospective healthcare reform; (7) the challenges and uncertainties in the
implementation of our expansion and development strategy; (8) the dependence on
key personnel; (9) adverse conditions in the stock market, the public debt
market, and other capital markets (including changes in interest rate
conditions); (10) the strength of the United States economy in general and the
strength of the local economies in which we conduct operations may be different
than expected resulting in, among other things, a reduced demand for practice
management services; (11) the demand for our products and services; (12)
technological changes; (13) the ability to increase market share; (14) the
adequacy of expense projections and estimates of impairment loss; (15) the
impact of change in accounting policies by the Securities and Exchange
Commission; (16) unanticipated regulatory or judicial proceedings; (17) the
impact on our business, as well as on the risks set forth above, of various
domestic or international military or terrorist activities or conflicts; (18)
other factors described in this report and in our other reports filed with the
Securities and Exchange Commission; and (19) our success at managing the risks
involved in the foregoing.


                                     PART I
                              FINANCIAL INFORMATION
                                     ITEM 2


     MANAGEMENT'S  DISCUSSION  AND  ANALYSIS OF  FINANCIAL  CONDITION,  CRITICAL
ACCOUNTING POLICIES AND RESULTS OF OPERATIONS

The following discussion and analysis provides information, which we believe, is
relevant to an assessment and understanding of our consolidated results of
operations and financial condition. This discussion should be read in
conjunction with the consolidated financial statements and notes thereto.

Critical Accounting Policies

We have adopted accounting policies, which we believe will result in an accurate
presentation of the financial statements. We consider critical accounting
policies to be those that require more significant judgments and estimates in
the preparation of our financial statements and include the following: (1)
revenue recognition; (2) allowance for doubtful accounts; (3) consideration of
impairment of intangible assets; and (4) valuation reserve on net deferred tax
assets.

Revenue recognition -

We record revenues at the estimated net amount that we expect to receive from
patients, employers, third party payors, and others at the time we perform the
services. We record contractual allowances when we prepare the related bills to
our customers. We bill some third parties at discounted and negotiated amounts.
Because we bill at the discounted amounts, we do not need to estimate third
party settlements.

Allowance for doubtful accounts -

 We maintain our allowances for doubtful accounts for estimated losses, which
may result from the inability of our customers to make required payments.
Allowances are based on the likelihood of recoverability of accounts receivable
considering such factors as past experience and taking into account current
collection trends that are expected to continue. Factors taken into
consideration in estimating the reserves are amounts past due, in dispute, or a
client that we believe might be having financial difficulties. If economic,
industry, or specific customer business trends worsen beyond earlier estimates,
we increase the allowances for doubtful accounts by recording additional
expense.

Consideration of impairment of intangible assets -

We evaluate the recovery of the carrying amount of excess of cost over fair
value of assets acquired by determining if a permanent impairment has occurred.
This evaluation is done annually or more frequently if indicators of permanent
impairment arise. Indicators of a permanent impairment include, among other
things, significant adverse change in legal factors or the business climate, an
adverse action by a regulator, unanticipated competition, loss of key personnel
or allocation of goodwill to a portion of business that is to be sold or
otherwise disposed. As we allocate any excess of cost over fair value of assets
acquired on a center-by-center basis, we compare our centers fair value to our
carrying value for impairment issues. We perform our impairment test on
September 30th of each year. In addition to the annual impairment test, we are
required to perform an impairment test any time an indicator occurs, such as
those noted above. At such time as an impairment is determined, the intangible
assets are written off during that period. Although considerable care is taken
to ensure that impairment losses are recorded as soon as indicators of
impairment are noted, material differences could occur if different, but
nonetheless reasonably plausible, indicators existed.

Valuation reserve on net deferred tax assets -

We record a valuation allowance to reduce our deferred tax assets to the amount
that is more likely than not to be realized. As of June 30, 2002, we recorded a
valuation allowance that reduced our deferred tax assets to equal our deferred
tax liability.

Our consolidated financial statements include the accounts of UCI, UCI-SC,
UCI-GA and the P.A.'s. Such consolidation is required under Emerging Issues Task
Force (EITF) 97-2 as a consequence of the nominee shareholder arrangement that
exists with respect to each of the P.A.'s. In each case, the nominee (and sole)
shareholder of the P.A. has entered into an agreement with UCI-SC or UCI-GA, as
applicable, which satisfies the requirements set forth in footnote 1 of EITF
97-2. Under the agreement, UCI-SC or UCI-GA, as applicable, in its sole
discretion, can effect a change in the nominee shareholder at any time for a
payment of $100 from the new nominee shareholder to the old nominee shareholder,
with no limits placed on the identity of any new nominee shareholder and no
adverse impact resulting to any of UCI-SC, UCI-GA or the P.A. resulting from
such change.

In addition to the nominee shareholder arrangements described above, each of
UCI-SC and UCI-GA have entered into Administrative Service Agreements with the
P.A.'s. As a consequence of the nominee shareholder arrangements and the
Administrative Service Agreements, we have a long-term financial interest in the
affiliated practices of the P.A.'s. According to EITF 97-2, the application of
FASB Statement No. 94 (Consolidation of All Majority-Owned Subsidiaries), and
APB No. 16 (Business Combinations), UCI must consolidate the results of the
affiliated practices with those of UCI.

The P.A.'s enter into employment agreements with physicians for terms ranging
from one to three years. All employment agreements have clauses that allow for
early termination of the agreement if certain events occur such as the loss of a
medical license. Over 79% of the physicians employed by the P.A.'s are paid on
an hourly basis for time scheduled and worked at the medical centers. The other
physicians are salaried. Approximately 25 of the physicians have incentive
compensation arrangements; however, no amounts were accrued or paid that were
significant during our three prior fiscal years. Any incentive compensation is
based upon a percentage of non-ancillary collectible charges for services
performed by a provider. Percentages range from 3% to 17% and vary by individual
employment contract. As of December 31, 2002 and 2001, the P.A.'s employed 114
and 109 medical providers, respectively.

The net assets of the P.A.'s are not material for any period presented, and
intercompany accounts and transactions have been eliminated.

We do not allocate all indirect costs incurred at the corporate offices to the
Centers on a center-by-center basis. Therefore, all discussions below are
intended to be in the aggregate for us as a whole.

Chapter 11 Bankruptcy Filing

On November 2, 2001, we filed a voluntary petition for reorganization under
Chapter 11 of the United States Bankruptcy Code (the "Bankruptcy Code") in the
United States Bankruptcy Court for the District of South Carolina (the
"Bankruptcy Court"). As debtors-in-possession, we remained in possession of our
properties and assets, and our management continued to operate our business.

The Bankruptcy Court approved payment of certain pre-petition liabilities, such
as employee wages and benefits, and settlement of certain trade payable claims.
In addition, the Bankruptcy Court allowed for the retention of legal and
financial professionals to advise in the bankruptcy proceedings.

The Bankruptcy Court confirmed each of our Plans of Reorganization, as amended,
by August 8, 2002 and we have, therefore, emerged from the Chapter 11 protection
of the Bankruptcy Court.

Because holders of our existing voting shares immediately before confirmation
received more than 50% of the voting shares of the reorganized equity, we did
not qualify for fresh start accounting under SOP 90-7.

Results of Operations

UCI provides nonmedical management and administrative services for a network of
41 freestanding medical centers (the "Centers"), 39 of which are located
throughout South Carolina and two are located in Knoxville, Tennessee (29
operating as Doctorss.s Care in South Carolina, one as Doctor's Care in
Knoxville, Tennessee, and ten as Progressive Physical Therapy Services in South
Carolina and one as Progressive Physical Therapy Services in Knoxville,
Tennessee).

Revenues of $10,297,000 for the quarter ended December 31, 2002 reflect an
increase of $1,066,000 or 12% from those of the quarter ended December 31, 2001.
This increase is the result of an increase in the volume of ancillary services
(such as physical therapy and laboratory tests) being offered at our facilities.
An intense advertising campaign has also been launched in the upstate region of
South Carolina that has increased patient volume.

Pursuant to SFAS No. 142, we tested goodwill for impairment in the fourth
quarter of 2002, and we determined there has not been any impairment.

Patient encounters increased to approximately 113,000 in the first quarter of
fiscal year 2003 from 109,000 in the first quarter of fiscal year 2002.

During the past three fiscal years, we have continued our services provided to
members of HMOs. In these arrangements, we, through the P.A., act as the
designated primary caregiver for members of HMOs who have selected one of our
centers or providers as their primary care provider. In fiscal year 1994, we
began participating in an HMO operated by Companion HealthCare Corporation
(CHC), a wholly owned subsidiary of Blue Cross Blue Shield of South Carolina
(BCBS). BCBS, through CHC, is a primary stockholder of UCI. Including its
arrangement with CHC, we now participate in four HMOs and are the primary care
gatekeeper for more than 9,000 lives at December 31, 2002. As of December 31,
2002, all of these HMOs use a discounted fee-for-service basis for payment. HMOs
do not, at this time, have a significant penetration into the South Carolina
market. We are not certain if the market share of HMOs will grow in the areas in
which we operate clinics.

Sustained revenues in fiscal years 2003 and 2002 also reflect our continued
focus on occupational medicine and industrial health services (these revenues
are referred to as "employer paid" and "workers compensation" on the table
below). We developed focused marketing materials, including quarterly
newsletters for employers, which were developed to spotlight our services for
industry. We derived approximately 17% and 21% of our total revenues from these
occupational medicine services in the first quarter of 2003 and 2002,
respectively.

The following table breaks out our revenue and patient visits by revenue source
for the first quarter of fiscal years 2003 and 2002.

<TABLE>
<S>                                                         <C>          <C>            <C>           <C>
                                                                  Percent of                  Percent of
                             Payor                              Patient Visits                 Revenue
        ------------------------------------------------    ------------------------    -----------------------
                                                               2003         2002           2003        2002
                                                            ------------ -----------    ------------ ----------
                                                                16           16             11          14
        Patient Pay
                                                                10           10              5           6
        Employer Paid
                                                                 7           8               8           8
        HMO
                                                                10           10             12          15
        Workers Compensation
                                                                11           12              7           9
        Medicare/Medicaid
                                                                42           41             51          43
        Managed Care Insurance
                                                                 4           3               6           5
        Other (Commercial Indemnity, Champus, etc.)
</TABLE>

We earned an operating margin of $824,000 during the first quarter of fiscal
2003 as compared to an operating margin of $680,000 for the first quarter of
fiscal 2002.

Our management believes that the increase in margin was the increase in
ancillary services being offered to our patients. However, the personnel cost
increases that continue will place continuing pressure on our margin and are in
part attributable to increased cost-cutting pressures being applied by managed
care insurance payors that cover many of our patients. As managed care plans
attempt to cut costs, they typically increase the administrative burden of
providers by requiring referral approvals and by requesting hard copies of
medical records before they will pay claims. The number of patients at our
Centers that are covered by a managed care plan versus a traditional indemnity
plan continues to grow. Our management expects this trend to continue.

Depreciation and amortization expense decreased slightly to $235,000 in the
first quarter of fiscal 2003, down from $263,000 in the first quarter of fiscal
2002 and is the result of normal asset write-off. Interest expense decreased
from $202,000 in the first quarter of fiscal 2002 to $195,000 in the first
quarter of fiscal 2003.

Financial Condition at December 31, 2002

Cash and cash equivalents decreased by $212,000 during the quarter ended
December 31, 2002 mainly as a result of timing of payments and payroll.

Accounts receivable increased by $341,000 during the quarter and is related to
the timing of the keying of remittances from insurance carriers and an overall
increase in revenues.

Long-term debt decreased from $4,078,000 at September 30, 2002 to $3,776,000 at
December 31, 2002. Regular principal pay-downs of approximately $302,000 were
made during the quarter. Our management believes that it will be able to fund
debt service requirements out of cash generated through operations and does not
anticipate the availability of additional debt financing.



<PAGE>


Liquidity and Capital Resources

We require capital principally to fund growth (acquire new Centers), for working
capital needs, and for the retirement of indebtedness. We fund our capital
requirements and working capital needs through a combination of external
financing (including bank debt and proceeds from the sale of common stock to
Companion HealthCare Corporation and Companion Property & Casualty) and credit
extended by suppliers.

As of December 31, 2002, we have no material commitments for capital
expenditures or for acquisitions or start-ups.

Operating activities produced $308,000 of cash during the first quarter of
fiscal year 2003, compared with $996,000 during the first quarter of fiscal year
2002. This decrease is mainly due to the pre-payment of certain of our
liabilities, as noted in the increase in prepaid assets with an offset by an
increase in accounts receivable.

Investing activities used $57,000 in the first quarter of fiscal year 2002 as
compared to $217,000 in the first quarter of fiscal year 2003. This increase is
due to purchases of needed equipment for our operating sites.

Financing activities utilized $303,000 in cash during the quarter for debt
reduction.




<PAGE>




                                     ITEM 3

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to changes in interest rates primarily as a result of our
borrowing activities, which includes credit facilities with financial
institutions used to maintain liquidity and fund our business operations, as
well as notes payable to various third parties in connection with certain
acquisitions of property and equipment. The nature and amount of our debt may
vary as a result of future business requirements, market conditions, and other
factors. The definitive extent of our interest rate risk is not quantifiable or
predictable because of the variability of future interest rates and business
financing requirements. We do not currently use derivative instruments to adjust
our interest rate risk profile.

Approximately $1,400,000 of the Company's debt at December 31, 2002 was subject
to fixed interest rates and principal payments. Approximately $2,400,000 of our
debt at December 31, 2002 was subject to variable interest rates. Based on the
outstanding amounts of variable rate debt at December 31, 2002, our interest
expense on an annualized basis would increase approximately $24,000 for each
increase of one percent in the prime rate.

We do not utilize financial instruments for trading or other speculative
purposes, nor do we utilize leveraged financial instruments.




<PAGE>


                                     ITEM 4

                             CONTROLS AND PROCEDURES

Quarterly evaluation of the Company's Disclosure Controls and Internal Controls.
Within the 90 days prior to the date of this Quarterly Report on Form 10-Q, the
company evaluated the effectiveness of the design and operation of its
"disclosure controls and procedures" (Disclosure Controls), and its "internal
controls and procedures for financial reporting" (Internal Controls). This
evaluation (the "Controls Evaluation") was done under the supervision and with
the participation of management, including our Chief Executive Officer ("CEO")
and Chief Financial Officer ("CFO"). Rules adopted by the SEC require that in
this section of the Quarterly Report we present the conclusions of the CEO and
the CFO about the effectiveness of our Disclosure Controls and Internal Controls
based on and as of the date of the Controls Evaluation.

CEO and CFO Certifications. Appearing immediately following the Signatures
section of this Quarterly Report there is a form of Certification. The form of
Certification is required in accord with Section 302 of the Sarbanes-Oxley Act
of 2002 (the "Section 302 Certification"). This section of the Quarterly Report
that you are currently reading is the information concerning the Controls
Evaluation referred to in the Section 302 Certifications, and this information
should be read in conjunction with the Section 302 Certifications for a more
complete understanding of the topics presented.

Disclosure Controls and Internal Controls. Disclosure Controls are procedures
that are designed with the objective of ensuring that information required to be
disclosed in our reports filed under the Securities Exchange Act of 1934 (the
"Exchange Act"), such as this Quarterly Report, is recorded, processed,
summarized and reported within the time periods specified in the SEC's rules and
forms. Disclosure Controls are also designed with the objective of ensuring that
such information is accumulated and communicated to our management, including
the CEO and CFO, as appropriate to allow timely decisions regarding required
disclosure. Internal Controls are procedures that are designed with the
objective of providing reasonable assurance that (1) our transactions are
properly authorized; (2) our assets are safeguarded against unauthorized or
improper use; and (3) our transactions are properly recorded and reported, all
to permit the preparation of our financial statements in conformity with
generally accepted accounting principles.

Limitations on the Effectiveness of Controls. The company's management,
including the CEO and CFO, does not expect that our Disclosure Controls or our
Internal Controls will prevent all error and all fraud. A control system, no
matter how well conceived and operated, can provide only reasonable, not
absolute, assurance that the objectives of the control system are met. Further,
the design of a control system must reflect the fact that there are resource
constraints, and the benefits of controls must be considered relative to their
costs. Because of the inherent limitations in all control systems, no evaluation
of controls can provide absolute assurance that all control issues and instances
of fraud, if any, within the company have been detected. These inherent
limitations include the realities that judgments in decision-making can be
faulty, and that breakdowns can occur because of simple error or mistake.
Additionally, controls can be circumvented by the individual acts of some
persons, by collusion of two or more people, or by management override of the
control. The design of any system of controls also is based in part upon certain
assumptions about the likelihood of future events, and there can be no assurance
that any design will succeed in achieving its stated goals under all potential
future conditions; over time, control may become inadequate because of changes
in conditions, or the degree of compliance with the policies or procedures may
deteriorate. Because of the inherent limitations in a cost-effective control
system, misstatements due to error or fraud may occur and not be detected.

Scope of the Controls Evaluation. The CEO/CFO evaluation of our Disclosure
Controls and our Internal Controls included a review of the controls' objectives
and design, the controls' implementation by the company and the effect of the
controls on the information generated for use in this Quarterly Report. In the
course of the Controls Evaluation, we sought to identify data errors, controls
problems or acts of fraud and to confirm that appropriate corrective action,
including process improvements, were being undertaken. This type of evaluation
will be done on at least a quarterly basis so that the conclusions concerning
controls effectiveness can be reported in our Quarterly Reports on Form 10-Q.
Our Internal Controls are also evaluated on an ongoing basis by other personnel
in our company and by our independent auditors in connection with their audit
and review activities. The overall goals of these various evaluation activities
are to monitor our Disclosure Controls and our Internal Controls and to make
modifications as necessary; our intent in this regard is that the Disclosure
Controls and the Internal Controls will be maintained as dynamic systems that
change (including with improvements and corrections) as conditions warrant.

Among other matters, we sought in our evaluation to determine whether there were
any "significant deficiencies" or "material weaknesses" in the company's
Internal Controls, or whether the company had identified any acts of fraud
involving personnel who have a significant role in the company's Internal
Controls. This information was important both for the Controls Evaluation
generally and because items 5 and 6 in the Section 302 Certifications of the CEO
and CFO require that the CEO and CFO disclose that information to our Board's
Audit Committee and to our independent auditors and to report on related matters
in this section of the Quarterly Report. In the professional auditing
literature, "significant deficiencies" are referred to as "reportable
conditions"; these are control issues that could have a significant adverse
effect on the ability to record, process, summarize and report financial data in
the financial statements. A "material weakness" is defined in the auditing
literature as a particularly serious reportable condition where the internal
control does not reduce to a relatively low level the risk that misstatements
caused by error or fraud may occur in amounts that would be material in relation
to the financial statements and not be detected within a timely period by
employees in the normal course of performing their assigned functions. We also
sought to deal with other controls matters in the Controls Evaluation, and in
each case if a problem was identified, we considered what revision, improvement
and/or correction to make in accord with our on-going procedures.

In accord with SEC requirements, the CEO and CFO note that, since the date of
the Controls Evaluation to the date of this Quarterly Report, there have been no
significant changes in Internal Controls or in other factors that could
significantly affect Internal Controls, including any corrective actions with
regard to significant deficiencies and material weaknesses.

Conclusions. Based upon the Controls Evaluation, our CEO and CFO have concluded
that, subject to the limitations noted above, our Disclosure Controls are
effective to ensure that material information relating to the company is made
known to management, including the CEO and CFO, particularly during the period
when our periodic reports are being prepared, and that our Internal Controls are
effective to provide reasonable assurance that our financial statements are
fairly presented in conformity with generally accepted accounting principles.



<PAGE>



                                     PART II
                                OTHER INFORMATION



Item 1            Legal Proceedings

                  We are not a party to any pending litigation other than
                  routine litigation incidental to the business or that is
                  immaterial in amount of damages sought.

                  Chapter 11 Bankruptcy Filing

                  On November 2, 2001, we filed a voluntary petition for
                  reorganization under Chapter 11 of the United States
                  Bankruptcy Code (the "Bankruptcy Code") in the United States
                  Bankruptcy Court for the District of South Carolina (the
                  "Bankruptcy Court"). As debtors-in-possession we remained in
                  possession of our properties and assets, and our management
                  continued to operate our business. As debtors-in-possession,
                  we were authorized to continue to operate our businesses, but
                  we were not allowed to engage in transactions outside the
                  ordinary course of business without the approval, after notice
                  and an opportunity for a hearing, of the Bankruptcy Court.
                  Pursuant to the automatic stay provisions of the Bankruptcy
                  Code, all actions to collect pre-petition indebtedness of us,
                  as well as most other pending litigation against us, were
                  stayed. In addition, as debtors-in-possession, we had the
                  right, subject to the approval of the Bankruptcy Court and
                  certain other conditions, to assume or reject any pre-petition
                  executory contracts or unexpired leases.

                  The Bankruptcy Court approved payment of certain pre-petition
                  liabilities, such as employee wages and benefits, and
                  settlement of certain trade payable claims. In addition, the
                  Bankruptcy Court allowed for the retention of legal and
                  financial professionals to advise in the bankruptcy
                  proceedings.

                  The Bankruptcy Court confirmed each of our Plans of
                  Reorganization, as amended, by August 8, 2002, and we have,
                  therefore, emerged from the Chapter 11 protection of the
                  Bankruptcy Court.

Item 2            Changes in Securities

                  This item is not applicable.

Item 3            Defaults upon Senior Securities

                  This item is not applicable.

Item 4            Submission of Matters to a Vote of Security Holders

                  This item is not applicable.

Item 5            Other Information

                  This item is not applicable.



<PAGE>


Item 6            Exhibits and Reports on Form 8-K

(a) Exhibits. This item is not applicable.

(b) Reports on Form 8-K.

                  UCI filed a Form 8-K on August 16, 2002 to report that the
                  United States Bankruptcy Court for the District of South
                  Carolina had confirmed plans of reorganization filed by UCI,
                  its wholly-owned subsidiaries, and certain of our affiliates
                  in connection with such entities' voluntary petition for
                  protection under Chapter 11 of the Bankruptcy Code.

                  UCI filed a Form 8-K on October 28, 2002 to report that UCI's
                  Board of Directors had approved an amendment to UCI's Amended
                  and Restated Bylaws dated November 23, 1993, as amended. Such
                  amendment specifies the procedure for business to be properly
                  brought before an annual or special meeting of stockholders
                  and the process for nominations for the election of directors
                  to UCI's Board of Directors.

                  UCI filed a Form 8-K on November 13, 2002 to report that UCI's
                  Board of Directors appointed D. Michael Stout, M.D. as the
                  President and Chief Executive Officer of UCI.






<PAGE>


                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


UCI Medical Affiliates, Inc.
         (Registrant)


------------------------------                 --------------------------------
D. Michael Stout, M.D.                         Jerry F. Wells, Jr., CPA
President and Chief Executive Officer          Executive Vice President,
                                               Chief Financial Officer and
                                               Principal Accounting Officer



Date:  February 12, 2003




<PAGE>


                                  CERTIFICATION

I, D. Michael Stout, M.D., certify that:

1.       I have reviewed this quarterly report on Form 10-Q of UCI Medical
         Affiliates, Inc.;

2.       Based on my knowledge, this quarterly report does not contain any
         untrue statement of a material fact or omit to state a material fact
         necessary to make the statements made, in light of the circumstances
         under which such statements were made, not misleading with respect to
         the period covered by this quarterly report;

3.       Based on my knowledge, the financial statements, and other financial
         information included in this quarterly report, fairly present in all
         material respects the financial condition, results of operations and
         cash flows of the registrant as of, and for, the periods presented in
         this quarterly report;

4.       The registrant's other certifying officers and I are responsible for
         establishing and maintaining disclosure controls and procedures (as
         defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and
         we have:

a)       Designed such disclosure controls and procedures to ensure that
         material information relating to the registrant, including its
         consolidated subsidiaries is made known to us by others within those
         entities, particularly during the period in which this quarterly report
         is being prepared;
b)       Evaluated the effectiveness of the registrant's disclosure controls and
         procedures as of a date within 45 days prior to the filing date of this
         quarterly report (the "Evaluation Date"); and
c)       Presented in this quarterly report our conclusions about the
         effectiveness of the disclosure controls and procedures based on our
         evaluation as of the Evaluation Date;
5.       The registrant's other certifying officers and I have disclosed, based
         on our most recent evaluation, to the registrant's auditors and the
         audit committee of registrant's board of directors (or persons
         performing the equivalent function):

a)       All significant deficiencies in the design or operation of internal
         controls which could adversely affect the registrant's ability to
         record, process, summarize and report financial data and have
         identified for the registrant's auditors any material weaknesses in
         internal controls; and
b)       Any fraud, whether or not material, that involves management or other
         employees who have a significant role in the registrant's internal
         controls; and
6.       The registrant's other certifying officers and I have indicated in this
         quarterly report whether or not there were significant changes in
         internal controls or in other factors that could significantly affect
         internal controls subsequent to the date of our most recent evaluation,
         including any corrective actions with regard to significant
         deficiencies and material weaknesses.



Date:  February 12, 2003                   /s/ D. Michael Stout, M.D.
                                           --------------------------
                                           D. Michael Stout, M.D.
                                           President & Chief Executive Officer



<PAGE>



                                  CERTIFICATION

I, Jerry F. Wells, Jr., CPA, certify that:

1.       I have reviewed this quarterly report on Form 10-Q of UCI Medical
         Affiliates, Inc.;

2.       Based on my knowledge, this quarterly report does not contain any
         untrue statement of a material fact or omit to state a material fact
         necessary to make the statements made, in light of the circumstances
         under which such statements were made, not misleading with respect to
         the period covered by this quarterly report;

3.       Based on my knowledge, the financial statements, and other financial
         information included in this quarterly report, fairly present in all
         material respects the financial condition, results of operations and
         cash flows of the registrant as of, and for, the periods presented in
         this quarterly report;

4.       The registrant's other certifying officers and I are responsible for
         establishing and maintaining disclosure controls and procedures (as
         defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and
         we have:

a)       Designed such disclosure controls and procedures to ensure that
         material information relating to the registrant, including its
         consolidated subsidiaries, is made known to us by others within those
         entities, particularly during the period in which this quarterly report
         is being prepared;
b)       Evaluated the effectiveness of the registrant's disclosure controls and
         procedures as of a date within 45 days prior to the filing date of this
         quarterly report (the "Evaluation Date"); and
c)       Presented in this quarterly report our conclusions about the
         effectiveness of the disclosure controls and procedures based on our
         evaluation as of the Evaluation Date;
5.       The registrant's other certifying officers and I have disclosed, based
         on our most recent evaluation, to the registrant's auditors and the
         audit committee of registrant's board of directors (or persons
         performing the equivalent function):

a)       All significant deficiencies in the design or operation of internal
         controls which could adversely affect the registrant's ability to
         record, process, summarize and report financial data and have
         identified for the registrant's auditors any material weaknesses in
         internal controls; and
b)       Any fraud, whether or not material, that involves management or other
         employees who have a significant role in the registrant's internal
         controls; and
6.       The registrant's other certifying officers and I have indicated in this
         quarterly report whether or not there were significant changes in
         internal controls or in other factors that could significantly affect
         internal controls subsequent to the date of our most recent evaluation,
         including any corrective actions with regard to significant
         deficiencies and material weaknesses.



Date: February 12, 2003                   /s/ Jerry F. Wells, Jr., CPA
                                          -----------------------------------
                                          Jerry F. Wells, Jr., CPA
                                          Executive Vice President
                                          and Chief Financial Officer


<PAGE>






<TABLE>
<S>                   <C>                                                       <C>
                                                                                  PAGE NUMBER OR INCORPORATION BY
 EXHIBIT NUMBER                                                                            REFERENCE TO
                                          DESCRIPTION
-----------------    -------------------------------------------------------    ------------------------------------

                                                                                                19
      99.1           Certification  Pursuant to 18 U.S.C.  Section 1350, as
                     adopted Pursuant to Section 906 of the  Sarbanes-Oxley
                     Act of 2002
                                                                                                20
      99.2           Certification  Pursuant to 18 U.S.C.  Section 1350, as
                     adopted Pursuant to Section 906 of the  Sarbanes-Oxley
                     Act of 2002

</TABLE>



<PAGE>


                                  EXHIBIT 99.1

     CERTIFICATION  PURSUANT TO 18 U.S.C.  SECTION  1350 AS ADOPTED  PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

         In connection with the quarterly report of UCI Medical Affiliates, Inc.
(the "Company) on Form 10-Q for the period ending December 31, 2002 as filed
with the Securities and Exchange Commission on the date hereof (the "Report"),
I, D. Michael Stout, M.D., President and Chief Executive Officer of the Company,
certify to the best of my knowledge, pursuant to 18 U.S.C. section 1350, as
adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002 that:

1. The Report fully complies with the requirements of section 13(a) or 15(d) of
the Securities Exchange Act of 1934; and 2. The information contained in the
Report fairly presents, in all material respects, the financial condition and
results of operations of the Company.

February 12, 2003                       /s/ D. Michael Stout, M.D.
                                        --------------------------
                                        D. Michael Stout, M.D.
                                        President and Chief Executive Officer


<PAGE>


                                  EXHIBIT 99.2

     CERTIFICATION  PURSUANT TO 18 U.S.C.  SECTION  1350 AS ADOPTED  PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

         In connection with the quarterly report of UCI Medical Affiliates, Inc.
(the "Company) on Form 10-Q for the period ending December 31, 2002 as filed
with the Securities and Exchange Commission on the date hereof (the "Report"),
I, Jerry F. Wells, Jr., CPA, Executive Vice President and Chief Financial
Officer of the Company, certify to the best of my knowledge, pursuant to 18
U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley
Act of 2002 that:

1. The Report fully complies with the requirements of section 13(a) or 15(d) of
the Securities Exchange Act of 1934; and 2. The information contained in the
Report fairly presents, in all material respects, the financial condition and
results of operations of the Company.

February 12, 2003                           /s/ Jerry F. Wells, Jr., CPA
                                            ----------------------------
                                            Jerry F. Wells, Jr., CPA
                                            Executive Vice President
                                            and Chief Financial Officer